Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingPE,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceHint,regularMarketChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,currency,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,shortName,exchangeDataDelayedBy,market,marketState,epsTrailingTwelveMonths,twoHundredDayAverageChangePercent,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,IDP.DE,2603000000,150555008,585100000,,616400000,462900000,448500000,637300000,2315300000,504000000,504000000,-15200000,-56400000,,,,-409100000,2775000000,2271000000,459700000,112400000,,1025500000,448500000,2385000000,13255600000,10751900000,1447000000,24470400000,100000,767900000,13900700000,2275300000,5763900000,-3148900000,1857300000,1742000000,3347200000,1849900000,-171800000,3844700000,7183700000,3435800000,1308800000,2110200000,7269200000,1254800000,375300000,-80100000,106700000,-152700000,-700000,-564500000,26300000,524500000,-450000000,14400000,1227300000,658800000,-700000,-81300000,174300000,-113800000,-106000000,-71900000,3836500000,en-US,US,EQUITY,False,Delayed Quote,1129,96.97,0.5150308,188.28 - 351.7,-66.45001,-0.18893947,188.28,351.7,1619094600,1634646600,1635165000,17.614548,70.931,286.21857,-0.9685669,-0.0033840113,257.17535,28.074646,42945814528,2,0.17559263,4.021514,15,Europe/Berlin,CEST,7200000,285.1 - 285.65,284.75,284.1,285.2,18,700,finmb_29726,XETRA,Biogen Inc.,USD,4242,EUR,False,False,285.25,1630572187,0.5,285.1,285.65,285.1,55,GER,"BIOGEN INC. DL -,0005",0,de_market,REGULAR,16.194,0.109165385,0.39,,,351.7,188.28,286.22,257.18,4.24k,1.13k,150.56M,,148.63M,0.68%,86.31%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",16.40%,24.03%,7.03%,22.14%,11.7B,76.48,-24.60%,11.64B,3.8B,1.92B,16.19,-70.90%,3.05B,20.47,7.63B,68.06,2.15,70.93,2.81B,2.41B,Value,02142,Healthcare,9100,9,6,"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 679 2000,MA,3,1609372800,1625097600,4,United States,http://www.biogen.com,86400,7,225 Binney Street,Drug Manufacturersâ€”General
t-1,IDP.DE,1931000000,150555008,514200000,,448800000,-19000000,410200000,595000000,2215900000,940100000,940100000,68500000,-64700000,,,,44200000,2694000000,1753900000,478100000,-491300000,,404600000,410200000,2988100000,13191500000,10682200000,1322500000,23854700000,100000,786100000,13833500000,2378500000,5763100000,-3151400000,1301500000,1217500000,3165800000,1286300000,-174300000,3852800000,6719500000,3229700000,1320000000,2224100000,7267200000,1171800000,430400000,-2900000,64800000,-64700000,-169300000,-785000000,-320700000,-113700000,-600000000,-33000000,769000000,102600000,2700000,-112500000,37200000,-15700000,587400000,-92600000,3553700000,en-US,US,EQUITY,False,Delayed Quote,1129,96.97,0.5150308,188.28 - 351.7,-66.45001,-0.18893947,188.28,351.7,1619094600,1634646600,1635165000,17.614548,70.931,286.21857,-0.9685669,-0.0033840113,257.17535,28.074646,42945814528,2,0.17559263,4.021514,15,Europe/Berlin,CEST,7200000,285.1 - 285.65,284.75,284.1,285.2,18,700,finmb_29726,XETRA,Biogen Inc.,USD,4242,EUR,False,False,285.25,1630572187,0.5,285.1,285.65,285.1,55,GER,"BIOGEN INC. DL -,0005",0,de_market,REGULAR,16.194,0.109165385,0.39,,,351.7,188.28,286.22,257.18,4.24k,1.13k,150.56M,,148.63M,0.68%,86.31%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",16.40%,24.03%,7.03%,22.14%,11.7B,76.48,-24.60%,11.64B,3.8B,1.92B,16.19,-70.90%,3.05B,20.47,7.63B,68.06,2.15,70.93,2.81B,2.41B,Value,02142,Healthcare,9100,9,6,"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 679 2000,MA,3,1609372800,1625097600,4,United States,http://www.biogen.com,86400,7,225 Binney Street,Drug Manufacturersâ€”General
t-2,IDP.DE,1853900000,150555008,1719800000,,370900000,-14200000,357900000,813200000,2362000000,-296200000,-296200000,66400000,-56000000,,,,13300000,2852600000,3148800000,490600000,667100000,,357600000,357900000,3084300000,13932800000,10700300000,1571200000,24618900000,100000,881100000,13976300000,2362400000,5762100000,-3276100000,1369500000,1331200000,3742200000,1369500000,-299000000,3844800000,6887100000,3671100000,1278900000,2327300000,7426200000,1068600000,454900000,-480200000,-82800000,-166400000,100000,-401100000,-145100000,-893600000,-400000000,41000000,-367100000,109700000,-8900000,-45700000,138500000,-1200000,-699600000,-86000000,3144900000,en-US,US,EQUITY,False,Delayed Quote,1129,96.97,0.5150308,188.28 - 351.7,-66.45001,-0.18893947,188.28,351.7,1619094600,1634646600,1635165000,17.614548,70.931,286.21857,-0.9685669,-0.0033840113,257.17535,28.074646,42945814528,2,0.17559263,4.021514,15,Europe/Berlin,CEST,7200000,285.1 - 285.65,284.75,284.1,285.2,18,700,finmb_29726,XETRA,Biogen Inc.,USD,4242,EUR,False,False,285.25,1630572187,0.5,285.1,285.65,285.1,55,GER,"BIOGEN INC. DL -,0005",0,de_market,REGULAR,16.194,0.109165385,0.39,,,351.7,188.28,286.22,257.18,4.24k,1.13k,150.56M,,148.63M,0.68%,86.31%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",16.40%,24.03%,7.03%,22.14%,11.7B,76.48,-24.60%,11.64B,3.8B,1.92B,16.19,-70.90%,3.05B,20.47,7.63B,68.06,2.15,70.93,2.81B,2.41B,Value,02142,Healthcare,9100,9,6,"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 679 2000,MA,3,1609372800,1625097600,4,United States,http://www.biogen.com,86400,7,225 Binney Street,Drug Manufacturersâ€”General
t-3,IDP.DE,1679200000,150555008,1140900000,,944700000,-14000000,701500000,573100000,2927000000,1076700000,1076700000,73000000,-56300000,,,,240800000,3376100000,2299400000,449100000,-132000000,,703900000,701500000,3323600000,14189600000,10758500000,1859900000,24934100000,100000,683500000,13961000000,2551500000,5755700000,-3202600000,1375200000,2224800000,3804000000,1372900000,-225500000,3794100000,7843100000,2842400000,1355000000,2552100000,7425000000,1027700000,398400000,465600000,-489300000,-52400000,100000,-1312900000,621300000,-160100000,-1250000000,24100000,1181100000,114700000,-10200000,-82400000,133100000,-62900000,182200000,-84100000,4039100000,en-US,US,EQUITY,False,Delayed Quote,1129,96.97,0.5150308,188.28 - 351.7,-66.45001,-0.18893947,188.28,351.7,1619094600,1634646600,1635165000,17.614548,70.931,286.21857,-0.9685669,-0.0033840113,257.17535,28.074646,42945814528,2,0.17559263,4.021514,15,Europe/Berlin,CEST,7200000,285.1 - 285.65,284.75,284.1,285.2,18,700,finmb_29726,XETRA,Biogen Inc.,USD,4242,EUR,False,False,285.25,1630572187,0.5,285.1,285.65,285.1,55,GER,"BIOGEN INC. DL -,0005",0,de_market,REGULAR,16.194,0.109165385,0.39,,,351.7,188.28,286.22,257.18,4.24k,1.13k,150.56M,,148.63M,0.68%,86.31%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",16.40%,24.03%,7.03%,22.14%,11.7B,76.48,-24.60%,11.64B,3.8B,1.92B,16.19,-70.90%,3.05B,20.47,7.63B,68.06,2.15,70.93,2.81B,2.41B,Value,02142,Healthcare,9100,9,6,"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 679 2000,MA,3,1609372800,1625097600,4,United States,http://www.biogen.com,86400,7,225 Binney Street,Drug Manufacturersâ€”General
